New PhRMA Report: Nearly 200 medicines in development for heart disease, stroke and other cardiovascular diseases

Ieva M. Augstums   |     December 9, 2015   |   SHARE THIS

Despite significant decreases in death rates from heart disease and stroke over the past three decades, these two conditions continue to be leading causes of death in the United States.


With more than 85 million Americans living with some type of cardiovascular disease, including more than six million adults who have had a stroke, chances are that you or someone you know would stand to benefit from new medicines that help prevent and treat these illnesses.

Fortunately, a new report released today from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Association of Black Cardiologists (ABC) shows that America’s biopharmaceutical companies are currently developing 190 medicines for heart disease and stroke – many of which will build on progress made by existing treatments.

These medicines, all of which are either in clinical trials or awaiting review by the U.S. Food and Drug Administration (FDA), include:

  • 33 for heart failure, which affects approximately 5.7 million American adults;
  • 29 for lipid disorders, including high cholesterol, which affects 30.9 million American adults with total cholesterol levels of more than 240;
  • 21 for stroke, which affects 6.6 million American adults;
  • 18 for peripheral vascular diseases, including critical limb ischemia and intermittent claudication;
  • 12 for hypertension, or high blood pressure, which affects 80 million American adults; and,
  • 12 for thrombosis, a condition characterized by coagulation or clotting of the blood in the veins or arteries (circulatory system).

A critical component of progressing research and development for heart disease and stroke medicines is clinical trial enrollment. To help drive that process, ABC established a Clinical Trials Network (CTN) that matches investigators with trials and helps recruit and retain African American patients for participation.

The combined efforts of innovative companies developing new medicines, along with the support of groups like ABC, creates hope that we can bring new treatments to people in need even faster while continuing to improve patient outcomes and survival rates.

View the full report here: Medicines in Development for Cardiovascular Diseases
View the medicine list here: Heart Disease, Stroke Drug List


Ieva M. Augstums

Ieva M. Augstums Ieva (YEH-vuh), Deputy Vice President of Public Affairs, joined PhRMA in 2014 and now oversees all branding and paid advertising, including PhRMA’s national multi-year GOBOLDLY campaign. She reported on the 2008 financial crisis and other financial market news during ten years as a journalist at the Dallas Morning News and the Associated Press, then directed national campaigns at a Washington-based strategic communications and brand consulting firm. A native Nebraskan, Ieva is a proud mother of two, dreams of opening a paperie and never passes up an opportunity to lace up for a rave run.

Topics: Medicines in Development, Research and Development, Heart Disease

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates